MDS/MPN with ring sideroblasts and thrombocytosis have been redefined in the 2022 WHO classification based on SF3B1 mutation and renamed MDS/MPN with SF3B1 mutation and thrombocytosis [107]. Here, SF3B1 is linked to myeloproliferative neoplasm.